tidutamab

Tidutamab (formerly XmAb18087) is a humanized, Fc domain-containing bispecific monoclonal antibody developed by Xencor. It targets both somatostatin receptor 2 (SSTR2), which is highly expressed on certain neuroendocrine tumor cells, and CD3, a T-cell surface antigen. By binding to these targets simultaneously, tidutamab redirects T-cell–mediated cytotoxicity specifically toward SSTR2-positive tumor cells. The drug has demonstrated the ability to induce acute and sustained T-cell activation in peripheral blood and has shown preliminary antitumor activity in early-phase clinical trials for neuroendocrine tumors (NETs), gastrointestinal stromal tumors (GIST), Merkel cell carcinoma, and small cell lung cancer[1][5][6][8]. Clinical development was discontinued for these indications after phase 1/phase 1/2 studies[5].

Other names

anti-SSTR2 x anti-CD3 monoclonal antibodyanti-SSTR-2 x anti-CD3 monoclonal antibodyanti-SSTR 2 x anti-CD3 monoclonal antibodySSTR2 x CD3SSTR-2 x CD3SSTR 2 x CD3